-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Earlier, Kyverna's Miv-Cel Meets All Primary And Secondary Endpoints In KYSA-8 Registrational Trial, Potentially First Approved Treatment For Stiff Person Syndrome

Benzinga·04/22/2026 07:11:38
Listen to the news
  • Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies – outcomes not previously observed in SPS
  • Data underscore potential for miv-cel to become the first and only approved treatment for SPS, fundamentally changing the treatme